Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway

被引:121
作者
Cheng, JQ
Jiang, XX
Fraser, M
Li, M
Dan, HC
Sun, M
Tsang, BK [1 ]
机构
[1] Univ Ottawa, Reprod Biol Unit, Dept Obstet & Gynecol & Cellular & Mol Med, Ottawa, ON, Canada
[2] Univ Ottawa, Div Gynaecol Oncol, Ottawa, ON, Canada
[3] Ottawa Civic Hosp, Ottawa Hlth Res Inst, Ottawa, ON K1Y 4E9, Canada
[4] Univ S Florida, Coll Med, Dept Pathol, Tampa, FL 33612 USA
[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
关键词
xiap; PI3K/Akt; ovarian cancer; chemoresistance;
D O I
10.1016/S1368-7646(02)00003-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Although cisplatin derivatives are first-line chemotherapeutic agents for the treatment of epithelial ovarian cancer, chemoresistance remains a major hurdle to successful therapy and the molecular mechanisms involved are poorly understood. Apoptosis is the cellular underpinning of cisplatin-induced cell death, which is associated with expression of specific "death" genes and down-regulation of "survival" counterparts. The X-linked inhibitor of apoptosis proteins (Xiap), an intracellular anti-apoptotic protein, plays a key role in cell survival by modulating death signaling pathways and is a determinant of cisplatin resistance in ovarian cancer cells in vitro. This review focuses on the role of Xiap and its interactions with the phosphoinositide-3 kinase (PI3K)/Akt cell survival pathway in conferring resistance of ovarian cancer cells to chemotherapeutic agents and discusses potential therapeutic strategies in overcoming chemoresistant ovarian cancer. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:131 / 146
页数:16
相关论文
共 157 条
[1]  
AHMED NN, 1993, ONCOGENE, V8, P1957
[2]  
ALTOMARE DA, 1995, ONCOGENE, V11, P1055
[3]  
*AM CANC SOC, 1997, CANC FACTS FIG 1997
[4]   A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma [J].
Ambrosini, G ;
Adida, C ;
Altieri, DC .
NATURE MEDICINE, 1997, 3 (08) :917-921
[5]  
ANDREWS PA, 1992, CANCER RES, V52, P1895
[6]   Options for modulation of drug resistance in ovarian cancer [J].
Arts, HJG ;
Van der Zee, AGJ ;
De Jong, S ;
De Vries, EGE .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2000, 10 :47-52
[7]  
Asselin E, 2001, CANCER RES, V61, P1862
[8]   Ovarian surface epithelium: Biology, endocrinology, and pathology [J].
Auersperg, N ;
Wong, AST ;
Choi, KC ;
Kang, SK ;
Leung, PCK .
ENDOCRINE REVIEWS, 2001, 22 (02) :255-288
[9]  
Baker SJ, 1996, ONCOGENE, V12, P1
[10]  
BEHRENS BC, 1987, CANCER RES, V47, P414